Company intelligence / Profile preview
Exelixis, Inc.
Alameda, California, United Statesexelixis.com ↗
- Ownership
- Public · EXEL
- Employees
- ~800
- Development stage
- Other
01
Overview
Exelixis has successfully commercialized multiple oncology drugs—most notably CABOMETYX® (cabozantinib) for RCC and HCC—and continues to advance a robust pipeline of next-generation cancer therapies. The company’s clinical results have led to several FDA approvals for its lead products. Ongoing pivotal trials are evaluating new indications and combination regimens with immune checkpoint inhibitors.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesBiotherapeutics (including antibody-drug conjugates and bispecific antibodies)
- Industry
- Biotech
02
Drug pipeline
38 assets37 more assets in the full pipeline.
03
Partnerships
Merck & Co. – collaboration on zanzalintinib + KEYTRUDA Phase III trialArcus Biosciences – STELLAR‑009 trial collaborationCybrexa Therapeutics – CBX‑12 program partnership/regained rights in Feb.2024
04
Financials
- Market cap
- $17.3B
- Total revenue
- $2.3B
- Enterprise value
- $16.5B
Beyond the preview
Go deeper on Exelixis, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exelixis, Inc..